Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $57.53 -1.42%
Financial Fact:
General and administrative expenses: 2.28M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
General and administrative expenses: 2.28M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($0.60), $0.15 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $27.4 million versus the consensus estimate of $47.81 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-powered cyber threats light a fire under cybersecurity stocks
- Dollar Tree shares drop amid analyst downgrade pressure
- StoneX Reiterates Hold Rating on Spotify (SPOT)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
